Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
12 participants
INTERVENTIONAL
2015-10-31
2018-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33
NCT01864902
CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）
NCT03556982
Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL
NCT02799550
Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML
NCT05473221
Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
NCT03114670
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
allogeneic CART-33
infusions of allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
allogeneic CART-33
allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
allogeneic CART-33
allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with relapsed and/or refractory CD33 positive acute myeloid leukemia (AML)
* Estimated life expectancy ≥ 12 weeks (according to investigator's judgment)
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Exclusion Criteria
* CD33 negative leukemia
* Any uncontrolled active medical disorder that would preclude participation as outlined
* Pregnant or lactating women
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese PLA General Hospital
OTHER
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Huisheng Ai, MD
Role: STUDY_CHAIR
Affiliated Hospital of Academy of Military Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Affiliated Hospital of Academy of Military Medical Sciences
Beijing, Beijing Municipality, China
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Huisheng Ai, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CART-AML-2015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.